Full Press Release Details
dupixent dupilumab approved in the u s as the first new targeted therapy in over a decade for chronic spontaneous urticaria csu.
REGN
dupixent dupilumab approved in the u s as the first new targeted therapy in over a decade for chronic spontaneous urticaria csu
Key Takeaway: dupixent dupilumab approved in the u s as the first new targeted therapy in over a decade for chronic spontaneous urticaria csu